Addressing variability in newborn screening can prevent missed diagnoses and delays in early care intervention.
Site Search
CEO pledge is part of the Foundation’s ongoing commitment to strengthen the organization and better serve all people with CF
Orkambi® is now approved for use in children with cystic fibrosis ages 1-2 years who have two F508del mutations. This is the only modulator available to very young children with these mutations.
A transformative leader for more than two decades, Marshall will transition to advisory role
The funding will help support research into the development of potential new modulator therapies for people with cystic fibrosis with an F508del mutation.
Funding will support a Phase 2b trial of phage therapy for chronic Pseudomonas aeruginosa lung infections.
This year’s program marked the largest in-person advocacy event in the Foundation’s history.